Disc Medicine, Inc.
Disc Medicine, Inc.
- Market cap
- $2.88B
Your view on IRON
Overview
What the company does, where it operates, and who runs it.
About Disc Medicine, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John D. Quisel
- Headquarters
- 321 Arsenal Street, Watertown, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- John D. Quisel
- Headquarters
- 321 Arsenal Street, Watertown, MA, US
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases.
It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Disc Medicine, Inc.. Starting points for Disc Medicine, Inc.: EPS -$6.25, beta 2.01 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Disc Medicine, Inc.. Trailing twelve-month EPS for Disc Medicine, Inc. stands at -$6.25. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Buy
Targets, low to high
Analyst ratings
8 firms, last 12 months- Strong Buy0
- Buy8
- Hold0
- Sell0
- Strong Sell0
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$1.47 | −$1.51 | −$5.90 | −$5.95 |
| Lowest estimate | −$1.62 | −$1.54 | −$6.07 | −$7.17 |
| Highest estimate | −$1.39 | −$1.47 | −$5.80 | −$5.17 |
| Number of analysts | 7 | 5 | 9 | 9 |
| A year ago | −$1.62 | −$1.65 | −$6.01 | — |
| Growth vs a year ago | +9.3% | +8.4% | +1.8% | — |
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $3.70M | $0.00 | $3.16M | $43.54M |
| Lowest estimate | $3.70M | $0.00 | $1.61M | $8.61M |
| Highest estimate | $3.70M | $0.00 | $6.54M | $70.95M |
| Number of analysts | 9 | 0 | 7 | 10 |
| A year ago | $0.00 | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Disc Medicine, Inc.. Disc Medicine, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| AGIOAgios Pharmaceuticals, Inc. | Healthcare | Biotechnology | $1.7B | ||
| COAGHemab Therapeutics Holdings, Inc. Common Stock | Healthcare | Biotechnology | $1.8B | ||
| DMRADamora Therapeutics, Inc. | Healthcare | Biotechnology | $1.4B | ||
| GERNGeron Corporation | Healthcare | Biotechnology | $560.9M | ||
| PTGXProtagonist Therapeutics, Inc. | Healthcare | Biotechnology | $7.9B | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| RLFTFRelief Therapeutics Holding AG | Healthcare | OTC | $11.9M | ||
| RLFTYMindMaze Therapeutics Holding S.A. Sponsored ADR | Healthcare | OTC | $12.0M | ||
| RLMDRelmada Therapeutics, Inc. | Healthcare | NASDAQ | $279.5M | ||
| RLYBRallybio Corporation | Healthcare | NASDAQ | $83.3M | ||
| RMTGRegenerative Medical Technology Group Inc. | Healthcare | OTC | $488,770 | ||
| RNAAvidity Biosciences, Inc. | Healthcare | NASDAQ | $149.3M | ||
| RNACCartesian Therapeutics, Inc. | Healthcare | NASDAQ | $187.3M | ||
| RNAZTransCode Therapeutics, Inc. | Healthcare | NASDAQ | $1.2M | ||
| RNTXRein Therapeutics Inc. | Healthcare | NASDAQ | $29.1M | ||
| RNUGFReNeuron Group plc | Healthcare | OTC | $62,891 | ||
| RNXTRenovoRx, Inc. | Healthcare | NASDAQ | $45.5M | ||
| ROIVRoivant Sciences Ltd. | Healthcare | NASDAQ | $28.0B | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | $689.2B in assets | 0.00% | |
| IWMiShares Russell 2000 ETF | $76.6B in assets | 0.09% | |
| XBIState Street SPDR S&P Biotech ETF | $10.0B in assets | 0.58% | |
| VXFVanguard Extended Market ETF | $30.2B in assets | 0.04% | |
| SBIOALPS Medical Breakthroughs ETF | $187M in assets | 2.07% | |
| VTWGVanguard Russell 2000 Growth ETF | $1.4B in assets | 0.17% | |
| TMSLT. Rowe Price Small-Mid Cap ETF | $3.2B in assets | 0.17% | |
| IBBiShares Biotechnology ETF | $11.1B in assets | 0.16% | |
Largest holders first, then the funds most concentrated in IRON.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Disc Medicine, Inc., and how their positions are changing. At a $2.88B market value, institutional positions materially move Disc Medicine, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Disc Medicine, Inc. executives and directors. Shares of Disc Medicine, Inc. have traded between $30.82 and $95.95 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Disc Medicine, Inc.. Coverage tracks Disc Medicine, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Disc Medicine, Inc.